Ways to increase public awareness of the pharmacovigilance system
Abstract
The purpose of this work was to identify ways to increase public awareness of the monitoring system for adverse drug reactions.
For this purpose, a systematic analysis of the literature from available sources in the MEDLINE (PubMed), Trip Database, Cochrane Library databases was carried out.
The main way to collect information about adverse drug reactions for pharmacovigilance is through a system of spontaneous reports that can be sent by healthcare professionals and patients. Today, both the WHO and the European Union recognize the importance of direct patient reporting in order to detect new and rare adverse reactions in a timely manner. However, despite this, there are problems of under-reporting of adverse drug reactions and patient’s low awareness of the pharmacovigilance system. This publication analyzes the reasons for under-reporting and activities aimed at promoting and increasing the number of reports of adverse reactions based on the experience of different countries.
Given the difference in cultures and values of countries, as well as the variability of conditions today, the methods used may not always be suitable for a complete solution of the problem. Therefore, the development of new and adaptation of already created methods is a topical issue today.
About the Authors
A. B. Esenbekova
Karaganda medical university
Kazakhstan
Kazakhstan
Karaganda
A. Zh. Bolatbek
Karaganda medical university
Kazakhstan
Kazakhstan
Karaganda
I. V. Losseva
Karaganda medical university
Kazakhstan
Kazakhstan
Karaganda
References
1. Aseckaya I. L. Sistema farmakonadzora v Evrazijskom e’konomicheskom soyuze / I. L. Aseckaya, S. K. Zyryanov, A. S. Kolbin, D. Yu. Belousov // Kachestvennaya klinicheskaya praktika. – 2018. – №4. – С. 53-72.
2. Prikaz Ministra zdravooxraneniya Respubliki Kazaxstan ot 23 dekabrya 2020 goda № ҚR DSM-320/2020 «Ob utverzhdenii pravil provedeniya farmakonadzora i monitoringa bezopasnosti, kachestva i e’ffektivnosti medicinskix izdelij».
3. Farmakonadzor i monitoring pobochnyx dejstvij [E’lektronnyj resurs] / Nacional’nyj centr e’kspertizy lekarstvennyx sredstv i medicinskix izdelij. – E’lektron. tekstovye dan. – Rezhim dostupa: https://www.ndda.kz/pages/farmakonadzor-imonitoring-pobochnykh-deistvii_1453112234. – Zagl. s e’krana.
4. Al Dweik R. Factors affecting patient reporting of adverse drug reactions: a systematic review / R. Al Dweik, D. Stacey, D. Kohen, S. Yaya // British Journal of Clinical Pharmacology. – 2017. – V. 83 (4). – P. 875-883.
5. Almandil Noor B. Healthcare professionals’ awareness and knowledge of adverse drug reactions and pharmacovigilance / Noor B. Almandil // Saudi Medical Journal. – 2016. – V. 37 (12). – P. 1359-1364.
6. Alomar M. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future / M. Alomar, A. M. Tawfiq, N. Hassan, S. Palaian // Therapeutic Advances in Drug Safety. – 2020. – V. 11. – ISSN 2042-0986.
7. Bahk C. Y. Increasing Patient Engagement in Pharmacovigilance Through Online Community Outreach and Mobile Reporting Applications: An Analysis of Adverse Event Reporting for the Essure Device in the US / C. Y. Bahk, M. Goshgarian, K. Donahue, C. C. Freifeld, C. M. Menone, C. E. Pierce, H. Rodriguez, J. S. Brownstein, R. Furberg, N. Dasgupta // Pharmaceutical Medicine. – 2015. – V. 29 (6). – P. 331-340.
8. de Vries S. T. Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK / S. T. de Vries, P. Denig, A. Andrić, Di Giusti M. Dimov, A. Ptaszynska-Neophytou, L. Härmark, P. G. M. Mol ; on behalf of the IMI Web-RADR Work Package 3b Consortium and SCOPE Joint Action Work Package 4 // Drug Safety. – 2021. – V. 44 (10). – P. 1073-1083.
9. Hadi M. A. Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting / M. A. Hadi, C. F. Neoh, R. M. Zin, M. E. Elrggal, E. Cheema // Integrated Pharmacy Research and Practice. – 2017. – V. 6. – P. 91-98.
10. Inácio P. The value of patient reporting to the pharmacovigilance system: a systematic review / P. Inácio, A. Cavaco, M. Airaksinen // British Journal of Clinical Pharmacology. – 2017. – V. 83 (2). – P. 227-246.
11. Islam M. A. Public Awareness about Medicine Information, Safety, and Adverse Drug Reaction (ADR) Reporting in Dammam, Saudi Arabia / M. A. Islam, A. F. Al-Karasneh, A. A. Naqvi, D. M. AlShayban, F. Al-Hayek, S. Al-Badrani, R. AlSalem, S. A. Ghori // Pharmacy. – 2020. – V. 8 (4) : 222.
12. Ito S. Estimation of the Under-Reporting of Suspected Serious Adverse Drug Reactions in Japan Using An Interrupted Time Series Analysis / S. Ito, M. Narukawa // Therapeutic Innovation & Regulatory Science. – 2022. – V. 56 (2). – P. 358-365.
13. Kim S. A cross-sectional survey of knowledge, attitude, and willingness to engage in spontaneous reporting of adverse drug reactions by Korean consumers / S. Kim, Y. M. Yu, M. You, K. H. Jeong, E. Lee // BMC Public Health. – 2020. – V. 20 : 1527.
14. Lopez-Gonzalez E. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial / E. Lopez-Gonzalez, M. T. Herdeiro, M. Piñeiro-Lamas, A. Figueiras ; On behalf of the GREPHEPI group // Drug Safety. – 2015. – V. 38 (2). – P.189-196.
15. Ribeiro-Vaz I. How to promote adverse drug reaction reports using information systems - a systematic review and meta-analysis/ I. RibeiroVaz, A. M. Silva, C. Costa Santos, R. Cruz-Correia // BMC Medical Informatics and Decision Making. – 2016. – V. 16 : 27.
16. Safety monitoring of medical products: reporting system for the general public [Электронный ресурс] / World Health Organization. – Электрон. текстовые дан. – Geneva: World Health Organization. – 2012. – 26 p. – ISBN 9789241503198.
17. Sales I. Public awareness and perception toward Adverse Drug Reactions reporting in Riyadh, Saudi Arabia / I. Sales, H. Aljadhey, Y. Albogami, M. A. Mahmoud // Saudi Pharmaceutical Journal. – 2017. – V. 25 (6). – P. 868-872.
18. Salgueiro E. What can we learn from the public’s understanding of drug information and safety? A population survey / E. Salgueiro, C. Gurruchaga, F. J. Jimeno, C. Martínez-Múgica, L. H. Martín Arias, G. Manso // International Journal of Pharmacy Practice. – 2019. – V. 27 (1). – P. 96-104.
19. Sandberg A. Under-Reporting of Adverse Drug Reactions in Finland and Healthcare Professionals’ Perspectives on How to Improve Reporting / A. Sandberg, V. Salminen, S. Heinonen, M. Sivén // Healthcare. – 2022. – V. 10 (6) : 1015
20. Suyagh M. Pharmacist’s knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process / M. Suyagh, D. Farah, R. Abu Farha // Saudi Pharmaceutical Journal. – 2015. – V. 23 (2). – P. 147-153.
21. Vaismoradi M. Adverse Drug Reactions in Norway: A Systematic Review / M. Vaismoradi, P. A. Logan, S. Jordan, H. Sletvold // Pharmacy. – 2019. – V. 7 (3) : 102
22. van Hunsel F. Experiences with adverse drug reaction reporting by patients: an 11-country survey / F. van Hunsel, L. Härmark, S. Pal, S. Olsson, K. van Grootheest // Drug Safety. – 2012. – V. 35 (1). – P. 45-60.
23. van Hunsel F. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands / F. van Hunsel, C. van der Welle, A. Passier, E. van Puijenbroek, K. van Grootheest // European Journal of Clinical Pharmacology. – 2010. – V. 66 (11). – P. 1143-1150.
Review
For citations:
Esenbekova A.B., Bolatbek A.Zh., Losseva I.V. Ways to increase public awareness of the pharmacovigilance system. Medicine and ecology. 2022;(3):33-38. (In Russ.)
Views: 213
Email this article 